University of Edinburgh student startup, health tech company Bioliberty, has secured £7.7m in a Series A investment round.
The round was led by £3m from the Scottish National Investment Bank (SNIB), alongside capital from existing investors Archangels, Eos Advisory, Old College Capital - the University’s in-house venture investment fund - and Hanna Capital SEZC, as well as new investor Conduit Connect. The full round is expected to close later in the year.
Bioliberty, which emerged from the University of Edinburgh’s School of Engineering, develops technology that supports physical rehabilitation for the increasing number of people recovering from mobility-limiting conditions or injuries.
The platform combines AI with soft-robotic wearable devices to help therapists deliver higher-intensity therapy while capturing clear, objective data on patient recovery. This approach makes therapy more efficient, helps accelerate progress, and gives clinical teams the visibility they need to make more informed decisions and coordinate care more effectively.
The funding will support continued product development and manufacturing in Scotland and will enable further commercial expansion in the United States, where the company’s technology is already used in several leading rehabilitation facilities.
Rowan Armstrong, CEO of Bioliberty, co-founded the company in 2019 with fellow Engineering graduate Ross O’Hanlon, alongside Conan Bradley and Shea Quinn, with support from Edinburgh Innovations and early investment from Old College Capital. He said:
This investment allows us to significantly expand our capabilities, from advancing how we measure patient recovery using computer vision and AI-driven assessments, to extending our product into patients’ homes.
Scotland has provided a strong foundation for Bioliberty, offering access to world-class engineering talent and a highly collaborative research environment. This funding will enable us to grow our team in Scotland, create high-value jobs, and continue building technology here that supports better rehabilitation outcomes.”
Bioliberty is headquartered at The National Robotarium in Edinburgh, the UK’s centre for robotics and artificial intelligence research, with manufacturing based in Fife. The company opened its U.S. headquarters in Boston in 2025, supporting its international operations while maintaining core product development activity in Scotland.
Katharine Fox, Head of Investment at Old College Capital, said:
Bioliberty is an example of world‑class engineering from the University of Edinburgh translating into better patient outcomes. Their AI‑enabled soft‑robotics platform is reshaping rehabilitation by giving clinicians clearer data and patients faster progress, and this funding will scale manufacturing in Scotland while accelerating growth in the U.S.
OCC has backed Bioliberty from the start, and we are proud to continue this support as it grows from a student startup into an international health‑tech company.”
